BioAge Labs Inc.
BIOA
Rank in Stocks
#15309
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The companyโs technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Share Price
$5.87
Last synced: 2026-11-11
Market Cap
$269.50M
Change (1 day)
1.56%
Change (1 year)
-26.72%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade BioAge Labs Inc. (BIOA)
Category
Healthcare
Operating Margin for BioAge Labs Inc. (BIOA)
Operating Margin as of November 2026 TTM: -1,026.28%
According to BioAge Labs Inc.'s latest financial reports, its current operating margin (TTM) is -1,026.28%. At the end of 2025 the company had an operating margin of -1,031.46%.
Operating Margin history for BioAge Labs Inc. from 2022 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,026.28% | -0.50% |
| 2025 | -1,031.46% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioAge Labs Inc.'s operating margin
What is BioAge Labs Inc.'s operating margin?
BioAge Labs Inc.'s operating margin is -1,026.28%, as of Nov 2026.
What was BioAge Labs Inc.'s operating margin in 2025?
In 2025, BioAge Labs Inc.'s operating margin was -1,031.46%, compared with 0.00% in 2024.
How has BioAge Labs Inc.'s operating margin changed since 2022?
From 2022 to 2025, BioAge Labs Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-1,031.46%).
How does BioAge Labs Inc.'s operating margin compare with similar companies?
BioAge Labs Inc.'s operating margin (-1,026.28%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.